| Literature DB >> 33490180 |
Kai Ren1, Weixun Duan1, Zhuowen Liang2, Bo Yu1, Buying Li1, Zhengxiao Jin1, Yimin Zhao3, Chao Xue1, Shiqiang Yu1, Jincheng Liu1, Xufeng Wei1.
Abstract
BACKGROUND: Bovine pericardium can be used for cardiovascular repair surgeries, but challenges involving biocompatibility and durability remain. This study aimed to carry out pre-clinical testing of aortic valve replacement using an aortic valve prosthesis made of bovine pericardium modified with glutaraldehyde (GA) and 2,3-butanediol (BD).Entities:
Keywords: Aortic valve defect; aortic valve replacement; bioprosthesis; bovine pericardium; butanediol; calcification; glutaraldehyde (GA)
Year: 2020 PMID: 33490180 PMCID: PMC7812161 DOI: 10.21037/atm-20-7803
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Mechanical testing
| Group | Elongation at breaking (%) | Tensile load (N) | Tensile strength (MPa) |
|---|---|---|---|
| Control | 16.3±3.5 | 22.0±2.8 | 18.8±3.3 |
| GA | 30.5±2.6* | 23.2±4.3 | 18.2±2.6 |
| GA + BD | 47.1±8.2*# | 41.5±1.7*# | 19.0±2.1 |
*, compared with the control group, P<0.05; #, compared with the GA group, P<0.05. GA, glutaraldehyde; BD, 2,3-butanediol.
Plasma protein adsorption test
| Group | Absorption (g/kg) |
|---|---|
| Control | 0.14±0.02 |
| GA | 0.20±0.03* |
| GA + BD | 0.13±0.02*# |
*, compared with the control group, P<0.05; #, compared with the GA group, P<0.05. GA, glutaraldehyde; BD, 2,3-butanediol.
Platelet adhesion test
| Group | Platelet adhesion (1012/kg) |
|---|---|
| Control | 1.34±0.21 |
| GA | 1.93±0.08* |
| GA + BD | 1.13±0.12*# |
*, compared with the control group, P<0.05; #, compared with the GA group, P<0.05. GA, glutaraldehyde; BD, 2,3-butanediol.
Collagenase digestion test
| Group | Undigested rate (%) |
|---|---|
| Control | 9.8±4.5 |
| GA | 77.1±16.7* |
| GA + BD | 82.6±8.9*# |
*, compared with the control group, P<0.05; #, compared with the GA group, P<0.05. GA, glutaraldehyde; BD, 2,3-butanediol.
Ninhydrin test
| Group | Ninhydrin (%) | Cross-section (%) |
|---|---|---|
| Control | 26.1±8.6 | – |
| GA | 14.9±3.5* | 56.7±3.9 |
| GA + BD | 11.5±4.6*# | 78.1±2.8# |
*, compared with the control group, P<0.05; #, compared with the GA group, P<0.05. GA, glutaraldehyde; BD, 2,3-butanediol.
Figure 1Histological observation of the new biomaterials after implantation for 8 weeks in rats (alizarin red staining, ×100). (A) Decellularized; (B) Decellularized and glutaraldehyde; (C) Decellularized, glutaraldehyde, and 2,3-butanediol.
Figure 2Histological observation of the new biomaterials after implantation for 8 weeks in rats (hematoxylin and eosin, ×100). (A) Decellularized; (B) Decellularized and glutaraldehyde; (C) Decellularized, glutaraldehyde, and 2,3-butanediol.
Figure 3Whole aortic valve bioprosthesis before and after implantation in sheep.
Figure 4Echocardiographic results after total aortic valve bioprosthesis implantation in sheep.
Echocardiographic results of artificial whole biological heart valves
| Echocardiographic indicator | Control (n=3) | Experimental group (n=10) |
|---|---|---|
| EOA (cm2) | 1.08±0.44 | 1.12±0.53 |
| Return percentage (%) | 1.42±0.47 | 1.47±0.49 |
| Blood flow (m/s) | 1.58±0.38 | 1.32±0.56* |
| LVSP (mmHg) | 75.42±8.58 | 75.96±8.27 |
| LVEDP (mmHg) | 4.82±2.35 | 4.83±3.58 |
| Ejection fraction (%) | 59±5 | 57±8 |
*, P<0.05 vs. control. EOA, effective orifice area; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure.
Hemodynamic changes after aortic valve replacement
| Hemodynamic indicator | Control (n=3) | Experimental group (n=10) |
|---|---|---|
| Mean arterial pressure (mmHg) | 90.0±12.9 | 88.4±15.5 |
| Left ventricular systolic pressure (mmHg) | 45.2±13.1 | 42.0±14.6* |
| Pulmonary artery pressure (mmHg) | 11.5±4.4 | 8.3±0.6* |
| Central venous pressure (mmHg) | 3.0±4.1 | 2.5±3.2 |
*, P<0.05 vs. controls.
Figure 5Laboratory test. (A) White blood cell count; (B) hemoglobin; (C) platelet count; (D) alanine transaminase (ALT); (E) urea nitrogen.
Figure 6Histological observation of different organs after implantation of the aortic valve bioprosthesis in sheep for 180 days. (A) Left ventricle; (B) right ventricle; (C) left atrium; (D) right atrium; (E) prosthetic valve leaflets; (F) artificial annulus; (G) perivascular tissue; (H) aortic wall; (I) lung; (J) liver; (K) spleen; (L) kidney; (M) brain. Hematoxylin and eosin, ×200.
Calcium content in the aortic valve prostheses
| Sheep# | Experimental group (μg/mg) | Control (μg/mg) |
|---|---|---|
| 01 | 1.64 | 2.2 |
| 02 | 0.92 | 15.09 |
| 03 | 1.08 | 7.4 |
| 04 | 2.99 | – |
| 05 | 16.81 | – |
| 06 | 4.52 | – |
| 07 | 1.51 | – |
| 08 | 1.44 | – |
| 09 | 2.03 | – |
#, one experimental animal in the 180-day group died unexpectedly on day 167. One experimental animal implanted in the control valve accidentally died on day 172.